Hay J G, McElvaney N G, Herena J, Crystal R G
Division of Pulmonary and Critical Care Medicine, New York Hospital-Cornell Medical Center, NY 10021, USA.
Hum Gene Ther. 1995 Nov;6(11):1487-96. doi: 10.1089/hum.1995.6.11-1487.
Mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) manifest on the nasal epithelial surface of individuals with cystic fibrosis (CF) by Na+ hyperabsorption and diminished beta-agonist-induced Cl- conductance, resulting in an abnormal bioelectric phenotype across the nasal epithelium. A clinical trial was conducted to determine if a replication-deficient, recombinant adenovirus vector containing a normal copy of the CFTR cDNA (AdCFTR) could, when administered to the nasal epithelium, correct the abnormal bioelectric phenotype. Nine individuals with CF received 2 x 10(5) to 2 x 10(8.5) plaque forming units of AdCFTR to the epithelium of one nostril. Measurements made included: baseline electrical potential difference (PD) between the surface of the nasal epithelium and the interstitial fluid, change in PD in response to amiloride, which inhibits apical Na+ channels, and change in PD in response to isoproterenol in a low Cl- solution, a measure of cAMP-regulated Cl- conductance. The functional integrity of the epithelium was evaluated by the PD response to ATP. Each individual served as their own control with measurements made in the nostril to be treated before AdCFTR administration, and in the contralateral untreated nostril. On the average, in the treated nostril over 2 weeks after the local administration of the adenovirus vector compared to measurements made in the same nostril before treatment, baseline PD decreased toward normal (-53.3 +/- 4.0 to -34.6 +/- 3.4, p = 0.01), response to amiloride decreased toward normal (36.9 +/- 4.7 to 19.7 +/- 3.0, p = 0.02), and response to low Cl- and isoproterenol increased toward normal (-4.5 +/- 1.5 to -9.1 +/- 2.1, p = 0.05). There were no changes in response to ATP (-15.3 +/- 2.7 to -15.8 +/- 1.9, p = 0.39), suggesting that the epithelium remained functionally intact. Importantly, there were no significant changes in measurements made in the untreated nostril. While limited to the nasal epithelium, these data suggest an adenovirus vector can safely deliver sufficient CFTR cDNA function to improve the abnormal CF bioelectric phenotype.
囊性纤维化跨膜传导调节因子基因(CFTR)的突变,在囊性纤维化(CF)患者的鼻上皮表面表现为钠(Na+)过度吸收以及β-激动剂诱导的氯(Cl-)传导减弱,导致鼻上皮细胞出现异常生物电表型。开展了一项临床试验,以确定携带CFTR cDNA正常拷贝的复制缺陷型重组腺病毒载体(AdCFTR),经鼻上皮给药后能否纠正这种异常生物电表型。9名CF患者的一侧鼻孔上皮接受了2×10⁵至2×10⁸.⁵个空斑形成单位的AdCFTR。测量指标包括:鼻上皮表面与组织液之间的基线电位差(PD)、对抑制顶端Na+通道的氨氯吡脒的反应导致的PD变化,以及在低氯溶液中对异丙肾上腺素的反应导致的PD变化(衡量环磷酸腺苷(cAMP)调节的Cl-传导)。通过PD对三磷酸腺苷(ATP)的反应来评估上皮的功能完整性。每位患者均以自身作为对照,在AdCFTR给药前对拟治疗的鼻孔以及对侧未治疗的鼻孔进行测量。平均而言,与治疗前在同一鼻孔所做的测量相比,在局部给予腺病毒载体2周后的治疗鼻孔中,基线PD向正常方向降低(从-53.3±4.0降至-34.6±3.4,p = 0.01),对氨氯吡脒的反应向正常方向降低(从36.9±4.7降至19.7±3.0,p = 0.02),对低氯溶液和异丙肾上腺素的反应向正常方向增加(从-4.5±1.5升至-9.1±2.1,p = 0.05)。对ATP的反应没有变化(从-15.3±2.7降至-15.8±1.9,p = 0.39),表明上皮功能保持完整。重要的是,在未治疗的鼻孔中所做的测量没有显著变化。虽然仅限于鼻上皮,但这些数据表明腺病毒载体能够安全地传递足够的CFTR cDNA功能,以改善CF异常生物电表型。